Extended Data Fig. 7: mRNA-1273 and SAS-adjuvanted S-2P protein elicit both IgG2a and IgG1 subclass S-binding antibodies.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a–f, BALB/cJ (a–c) or C57BL/6J (d–f) mice (n = 10/group) were immunized at weeks 0 and 3 with 0.01 (green), 0.1 (blue), or 1 μg (red) of mRNA-1273 or SARS-CoV-2 S-2P protein adjuvanted with SAS. Sera were collected 2 weeks post-boost and assessed by ELISA for SARS-CoV-2 S-specific IgG1 and IgG2a or IgG2c for BALB/cJ and C57BL/6J mice, respectively. End-point titres (a, b, d, e) and end-point titre ratios of IgG2a to IgG1 (c) and IgG2c to IgG1 (f) were calculated. For mice for which end-point titres did not reach the lower limit of detection (dotted line), ratios were not calculated (N/A). Data are presented as GMT ± geometric s.d. (a, b, d, e) or mean ± s.d. (c, f).
